MedTrace Logo

Clinical Efficacy and Long-term Outcomes of ALLOgraft Versus Stented Biological Prosthesis for Primary TRIcuspid Valve Disease (ALLOTRI)

NCT06591000 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2024-09-19

No results posted yet for this study

Summary

The aim of the study is to evaluate early safety, clinical efficacy and long-term outcomes of mitral allografts and stented biological prosthesis in tricuspid valve replacement for primary tricuspid valve diseases.

Conditions

  • Allograft
  • Bioprosthesis
  • Tricuspid Valve Disease

Interventions

PROCEDURE

tricuspid valve replacement

Complete or partial tricuspid valve replacement with mitral allograft/ complete tricuspid valve replacement with biological prosthesis

Sponsors & Collaborators

  • Chelyabinsk Regional Clinical Hospital

    lead OTHER_GOV

Principal Investigators

  • Yuri Malinovsky, PhD · Department of Cardiac Surgery

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-14
Primary Completion
2024-12-14
Completion
2025-06-14

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06591000 on ClinicalTrials.gov